ArticleCureus2026
Concurrent Catastrophic Antiphospholipid Syndrome, Hemophagocytic Lymphohistiocytosis, and Myocarditis Leading to Multi-organ Failure in a Patient With Systemic Lupus Erythematosus and Antiphospholipid Syndrome.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Catastrophic antiphospholipid syndrome (CAPS) is a fulminant and life-threatening manifestation of antiphospholipid syndrome (APLS), often presenting with rapid multi-organ dysfunction and high mortality despite aggressive therapy. Its associations with hemophagocytic lymphohistiocytosis (HLH) and lupus myocarditis are not well understood. We report the case of a 43-year-old woman with systemic lupus erythematosus (SLE) and secondary APLS who developed CAPS following elective mitral valve repair. Her course was complicated by renal cortical necrosis, recurrent lupus myocarditis, refractory immune thrombocytopenia, sepsis, and HLH, requiring multiple immunosuppressive modalities including corticosteroids, intravenous immunoglobulin, plasma exchange, rituximab, cyclophosphamide, and anakinra. Despite intensive multidisciplinary management across rheumatology, cardiology, nephrology, hematology, infectious diseases, and intensive care, she suffered progressive multi-organ failure and transitioned to palliative care. This case highlights the diagnostic and therapeutic complexity of overlapping autoimmune syndromes, the risks of surgical triggers in predisposed patients, and the challenges of balancing immunosuppression against infection in the setting of CAPS. It underscores the need for dynamic multidisciplinary collaboration, early recognition of HLH and lupus myocarditis overlap, and timely integration of palliative care when maximal therapy fails.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.